Multiple Sclerosis
Conditions
Keywords
Multiple Sclerosis, Non-exercise physical activity, NEPA, Cardiometabolic health, Comorbidities
Brief summary
This study evaluates the impact of reducing sitting time and increasing exercise time on cardiometabolic health in persons with Multiple Sclerosis.
Detailed description
To date, it is clear that sedentary behaviour is strongly related to an increased risk of type II diabetes, cardiovascular disease and premature mortality. People suffering from chronic disabilities appear to be particularly susceptible to a sedentary lifestyle and inactivity due to primary disease symptoms. To date, this is an important new research topic in Multiple Sclerosis (MS, \ 2.3 million people worldwide, \ 10-12.000 diagnosed in Belgium) treatment, since previous research reported a significantly higher prevalence of sedentary behaviour in persons with MS (PwMS) compared to healthy controls (HC). PwMS are reported to have a 40% lower daily step count compared to healthy inactive persons and tend to accumulate their sedentary time in longer bouts. As described above and similar to other chronic conditions, a sedentary lifestyle also makes PwMS more vulnerable to the accumulation of important cardiometabolic comorbidities that seem inactivity-related rather than a direct result of non-reversible tissue injury. Such comorbidities include impaired whole body glycaemic control, an abnormal blood lipid profile, an unhealthy body composition and hypertension. In this respect, it is important to note that corticosteroids, which are often used to treat MS patients pharmacologically, elevate fasting glucose and insulin concentrations and induce insulin resistance in HC therefore probably also increase several cardiometabolic risk factors in MS. Up to now, research in MS has been focused on structured exercise and its positive effects on functional parameters are well-known (e.g. improvements in cardiorespiratory fitness, muscle strength, balance, fatigue, cognition, quality of life and respiratory function). However, evidence is growing that sedentary time, independent of the (dis)practice of structured exercise, is an important independent health risk factor. Consequently, any strategy that also improves cardiometabolic health may help to further optimize rehabilitation in MS. Breaking up and reducing sedentary time with easy, daily activities such as household activities and other activities which increase light-intensity walking and standing, known as non-exercise physical activity (NEPA) may be such a strategy. NEPA has already been shown to significantly improve cardiometabolic risk markers in healthy, sedentary subjects, type II diabetes patients and obese adults and it involves lower intensity physical activities that are probably more feasible for PwMS. Moreover, with comparable activity workloads, reducing sitting time by NEPA of longer duration decreases insulin levels and fasting lipid levels more than performing one structured exercise bout of moderate intensity that is usually described in current activity guidelines. So far however, acute exercise bouts and NEPA effects on cardiometabolic health in this population have never been described. Therefore, the aim of this study is to investigate whether (1) cardiometabolic health (glycaemic control, blood lipids, inflammation markers and blood pressure) of persons with MS improves when sedentary time is reduced and (2) NEPA results in better cardiometabolic health parameters than (a shorter daily bout of) moderate-intensity exercise when workload of both activities is identical in this population.
Interventions
OTHERBaseline activity (control regime)
This is a baseline measurement of physical activity during which subjects will be instructed not to change activity patterns during four days and to note all activities they perform.
OTHERIncreased sitting time (sit regime)
Participants have to spend 14h of their day sitting, 1h walking and 1h standing, for four consecutive days. According to the compendium of Ainsworth et al. (2011), this corresponds with a daily workload of activities (DWA) of 27 metabolic equivalents (MET's) per day.
OTHERNon-exercise physical activity (sit less regime)
Each day (4 days in total) will consist of 3h walking, 4h standing and 9h sitting. These time frames are chosen to result in a comparable DWA increase as the exercise regime compared to the sit regime (+7 MET's)27. The additional 2h of walking and 3h of standing, compared to the sitting regime, will be done in a minimum of four bouts with a time interval of \> 1h. The subjects will be instructed to walk on a slow pace. i.e. 2-3 km/h (e.g. walking during shopping and work related walking in an office).
OTHERStructured exercise (exercise regime)
One hour of sitting in the sit regime will be replaced with 1 training session (1h) on a cycle ergometer in the research center. The remaining hours of each day (4 days in total) have to be spent as follows: 13h sitting, 1h walking and 1h standing for daily care. The intensity of the training session (50-60% of Wmax) results in a DWA of 34.5 MET's according to the compendium of physical activities. Duration of training sessions will be adapted individually with ActivPAL data of the sit less and sit regime to identically match DWA increase between the sit less and exercise regime, compared to the sitting regime.
Sponsors
Hasselt University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)
Masking description
The outcome assessor will not know the code of the different regimes.
Intervention model description
Participants will follow four regimes of 4 days each including a control, a sit less, a sit and an exercise regime. The order of the sit and sit less regimes will be randomized. Each activity regime will be followed by a wash-out period of 10 days during which subjects will continue their normal lifestyle.
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Signed informed consent * Men and women ≥18 years old * Clinical diagnosis of MS (McDonald criteria) * Expanded Disability Status Score ≤ 5 * Daily internet access
Exclusion criteria
* Reported participation in another biomedical trial which may have an effect on blood parameters one month before the pre-study examination or during the study * Blood donation in the past three months * Pregnancy or intention of becoming pregnant * Reported dietary habits: medically prescribed diet, slimming diet * Reported weight loss (\>2kg) in the last three months prior to the screening * Alcohol use \> 20 units per week (during the last 3 months) * Experimental drug use (during the last 3 months) * Medication changes (during the last month) * Medical conditions which make participation in the study not responsible: * Heart failure: New York Heart Association (NYHA) 3 or higher * Angina pectoris or signs of cardiac ischemia during exercise testing * Mental or physical disability * Based on historical information not able to walk for 3h per day and stand for 4h per day (e.g. intermittent claudication)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Concentration of interleukin 1 (IL-1) | Day after the control regime | Blood analysis |
| Concentration of free fatty acids (FFA) | Day after the control regime | Blood analysis |
| Concentration of C-reactive protein (CRP) | Day after the control regime | Blood analysis |
| Concentration of interleukin 6 (IL-6) | Day after the control regime | Blood analysis |
| Steps per day | Day 1 to 4 of the control regime | Physical activity will be measured with the ActivPAL3TM activity monitor (PAL Technologies Ltd, Glasgow, UK). |
| Sitting time | Day 1 to 4 of the control regime | Sedentary behaviour will be measured with the ActivPAL3TM activity monitor (PAL Technologies Ltd, Glasgow, UK). |
| Standing time | Day 1 to 4 of the control regime | Physical activity will be measured with the ActivPAL3TM activity monitor (PAL Technologies Ltd, Glasgow, UK). |
| Stepping time | Day 1 to 4 of the control regime | Physical activity will be measured with the ActivPAL3TM activity monitor (PAL Technologies Ltd, Glasgow, UK). |
| Concentration of glucose | Day after the control regime | Blood analysis |
| Concentration of insulin | Day after the control regime | Blood analysis |
| Concentration of total cholesterol | Day after the control regime | Blood analysis |
| Concentration of high density lipoprotein cholesterol (HDL-cholesterol) | Day after the control regime | Blood analysis |
| Concentration of low density lipoprotein cholesterol (LDL-cholesterol) | Day after the control regime | Blood analysis |
| Concentration of non-high densitiy lipoprotein cholesterol (non-HDL cholesterol) | Day after the control regime | Blood analysis |
| Concentration of triglyceride | Day after the control regime | Blood analysis |
| Concentration of apolipoprotein A1 (apo A1) | Day after the control regime | Blood analysis |
| Concentration of apolipoprotein B (apo B) | Day after the control regime | Blood analysis |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Body weight | Day after the Control regime | Body weight (in underwear) is determined using a digital-balanced weighting scale to the nearest 0.1kg |
| Blood pressure | Day after the Control regime | Systolic, diastolic and mean arterial blood pressure will be measured 3 times at 5-min intervals using an electronic sphygmomanometer (Omron®, Omron Healthcare, IL, USA) from the dominant arm and documented as the mean value of the final 2 measurements. |
Countries
Belgium
Outcome results
None listed